跳转至内容
Merck
CN

549835

Sigma-Aldrich

2,4,6-三(二甲氨基)均三嗪

96%

登录查看公司和协议定价

别名:
六甲三聚氰胺, 六甲蜜胺
经验公式(希尔记法):
C9H18N6
CAS号:
分子量:
210.28
EC 号:
MDL编号:
UNSPSC代码:
12352100
PubChem化学物质编号:
NACRES:
NA.22

质量水平

检测方案

96%

mp

171-175 °C (lit.)

SMILES字符串

CN(C)c1nc(nc(n1)N(C)C)N(C)C

InChI

1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3

InChI key

UUVWYPNAQBNQJQ-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

2,4,6-Tris(dimethylamino)-1,3,5-triazine exhibits antitumor activity.

象形图

Exclamation mark

警示用语:

Warning

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogues of the antitumour drug 2, 4, 6-tris (dimethylamino)-1, 3, 5-triazine (hexamethylmelamine).
Langdon SP, et al.
Journal of the Chemical Society. Perkin Transactions 1, 993-998 (1984)
Nina Keldsen et al.
Gynecologic oncology, 88(2), 118-122 (2003-02-15)
To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months.
D S Alberts et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 14(2), 224-228 (2004-04-17)
This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy. Patients who enrolled in the SWOG
Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
Mark R Green
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(19), 3112-3113 (2008-07-02)
R T Zon et al.
Investigational new drugs, 19(3), 229-231 (2001-09-20)
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门